Equities

Aligos Therapeutics Inc

Aligos Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.14
  • Today's Change-1.04 / -10.22%
  • Shares traded238.83k
  • 1 Year change-53.72%
  • Beta2.1840
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments136126191
Total Receivables, Net------
Total Inventory------
Prepaid expenses------
Other current assets, total5.387.7214
Total current assets141134204
Property, plant & equipment, net9.821315
Goodwill, net------
Intangibles, net------
Long term investments--015
Note receivable - long term------
Other long term assets0.630.630.87
Total assets152147235
LIABILITIES
Accounts payable2.524.743.02
Accrued expenses171827
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.010.110.14
Other current liabilities, total4.33119.15
Total current liabilities243339
Total long term debt0.230.230.39
Total debt0.240.340.53
Deferred income tax------
Minority interest------
Other liabilities, total359.4311
Total liabilities594351
SHAREHOLDERS EQUITY
Common stock0.010.000.00
Additional paid-in capital578503487
Retained earnings (accumulated deficit)(487)(399)(303)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.550.400.45
Total equity92104185
Total liabilities & shareholders' equity152147235
Total common shares outstanding6.004.694.68
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.